Download PDF
Geburtshilfe Frauenheilkd 2010; 70(10): 791-797
DOI: 10.1055/s-0030-1250398
Übersicht

© Georg Thieme Verlag KG Stuttgart · New York

Antiangiogene Ansätze in der Therapie des Ovarialkarzinoms

Antiangiogenic Approaches in Ovarian Cancer TherapyF. Heitz1 , P. Harter1 , J. Zelazny2 , A. du Bois1
  • 1Abteilung für Gynäkologie und gynäkologische Onkologie, Dr. Horst Schmidt Kliniken, Wiesbaden
  • 2Klinik und Poliklinik für Geburtshilfe und Frauenkrankheiten der Universitätsmedizin Mainz, Mainz
Further Information

Publication History

eingereicht 21.5.2010 revidiert 5.8.2010

akzeptiert 5.8.2010

Publication Date:
04 November 2010 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Patientinnen, die an einem Ovarialkarzinom erkrankt sind, haben trotz verbesserter therapeutischer Maßnahmen eine schlechte Prognose. Die ausreichende Versorgung mit Sauerstoff und Nährstoffen ist für Tumoren wie das Ovarialkarzinom essenziell. Verschiedene Mechanismen, v. a. die Angiogenese, bewirken eine dem Tumorwachstum angemessene Gefäßneubildung, um eine adäquate Versorgung des Tumors zu gewährleisten. Neue Substanzen, welche proangiogene Mediatoren abfangen oder die durch transmembrane Tyrosinkinaserezeptoren vermittelte intrazelluläre Signaltransduktion blockieren, werden zunehmend an Bedeutung gewinnen, da diese eine gute antitumoröse Aktivität aufweisen. Allerdings muss aufgrund der Wirkmechanismen mit bisher wenig bekannten Nebenwirkungen wie Hypertonie, Proteinurie, Diarrhö, Darmperforationen u. a. gerechnet werden und diese müssen konsekutiv adäquat behandelt werden.

Abstract

Despite promising therapeutic advances in the treatment of patients suffering from ovarian cancer, the prognosis remains poor. A sufficient supply of oxygen and nutrients is crucial for ovarian cancer, which is mainly provided by angiogenesis. The clinical use of new substances which trap proangiogenic substances or inhibit their intracellular transmembrane tyrosine kinase activity will increase as these substances have been shown to exhibit promising anti-tumorous activity. However, these new therapeutic approaches may lead to an increase in side effects such as diarrhea, hypertension, proteinuria, intestinal perforation and others, which are still relatively unknown, and these side effects will require adequate consecutive treatment.

Schlüsselwörter

Ovarialkarzinom - antiangiogenetische Substanzen - VEGF - Tyrosinkinaseinhibitoren - „small molecules“

Key words

ovarian cancer - antiangiogenic substances - VEGF - tyrosine kinase inhibitors - “small molecules”

Literatur

  • 1 Heintz A P, Odicino F, Maisonneuve P et al. Carcinoma of the ovary. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer.  Int J Gynaecol Obstet. 2006;  95 (Suppl. 1) S161-S192
    CrossrefPubMedGoogle Scholar
  • 2 Edmondson R J, Monaghan J M. The epidemiology of ovarian cancer.  Int J Gynecol Cancer. 2001;  11 423-429
    CrossrefPubMedGoogle Scholar
  • 3 du Bois A, Reuss A, Pujade-Lauraine E et al. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO).  Cancer. 2009;  115 1234-1244
    CrossrefPubMedGoogle Scholar
  • 4 Folkman J, Watson K, Ingber D et al. Induction of angiogenesis during the transition from hyperplasia to neoplasia.  Nature. 1989;  339 58-61
    CrossrefPubMedGoogle Scholar
  • 5 Ferrara N, Gerber H P, LeCouter J. The biology of VEGF and its receptors.  Nat Med. 2003;  9 669-676
    CrossrefPubMedGoogle Scholar
  • 6 Takahashi T, Yamaguchi S, Chida K et al. A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-A-dependent activation of PLC-gamma and DNA synthesis in vascular endothelial cells.  EMBO J. 2001;  20 2768-2778
    CrossrefPubMedGoogle Scholar
  • 7 Goodheart M J, Vasef M A, Sood A K et al. Ovarian cancer p 53 mutation is associated with tumor microvessel density.  Gynecol Oncol. 2002;  86 85-90
    CrossrefPubMedGoogle Scholar
  • 8 Raspollini M R, Castiglione F, Garbini F et al. Correlation of epidermal growth factor receptor expression with tumor microdensity vessels and with vascular endothelial growth factor expression in ovarian carcinoma.  Int J Surg Pathology. 2005;  13 135-142
    PubMedGoogle Scholar
  • 9 Byrne A T, Ross L, Holash J et al. Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model.  Clin Cancer Res. 2003;  9 5721-5728
    PubMedGoogle Scholar
  • 10 Shen G H, Ghazizadeh M, Kawanami O et al. Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma.  Br J Cancer. 2000;  83 196-203
    CrossrefPubMedGoogle Scholar
  • 11 Goodheart M J, Ritchie J M, Rose S L et al. The relationship of molecular markers of p 53 function and angiogenesis to prognosis of stage I epithelial ovarian cancer.  Clin Cancer Res. 2005;  11 3733-3742
    CrossrefPubMedGoogle Scholar
  • 12 Giantonio B J, Catalano P J, Meropol N J et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200.  J Clin Oncol. 2007;  25 1539-1544
    CrossrefPubMedGoogle Scholar
  • 13 Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.  N Engl J Med. 2004;  350 2335-2342
    CrossrefPubMedGoogle Scholar
  • 14 Sandler A, Gray R, Perry M C et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.  N Engl J Med. 2006;  355 2542-2550
    CrossrefPubMedGoogle Scholar
  • 15 Miller K, Wang M, Gralow J et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.  N Engl J Med. 2007;  357 2666-2676
    CrossrefPubMedGoogle Scholar
  • 16 Cannistra S A, Matulonis U A, Penson R T et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer.  J Clin Oncol. 2007;  25 5180-5186
    CrossrefPubMedGoogle Scholar
  • 17 Burger R A, Sill M W, Monk B J et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study.  J Clin Oncol. 2007;  25 5165-5171
    CrossrefPubMedGoogle Scholar
  • 18 Garcia A A, Hirte H, Fleming G et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia.  J Clin Oncol. 2008;  26 76-82
    CrossrefPubMedGoogle Scholar
  • 19 Chura J C, Van Iseghem K, Downs jr. L S et al. Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer.  Gynecol Oncol. 2007;  107 326-330
    CrossrefPubMedGoogle Scholar
  • 20 Micha J P, Goldstein B H, Rettenmaier M A et al. A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer.  Int J Gynecol Cancer. 2007;  17 771-776
    CrossrefPubMedGoogle Scholar
  • 21 Penson R T, Dizon D S, Cannistra S A et al. Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors.  J Clin Oncol. 2010;  28 154-159
    CrossrefPubMedGoogle Scholar
  • 22 Lockhart A C, Rothenberg M L, Dupont J et al. Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors.  J Clin Oncol. 2010;  28 207-214
    CrossrefPubMedGoogle Scholar
  • 23 Drevs J, Siegert P, Medinger M et al. Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors.  J Clin Oncol. 2007;  25 3045-3054
    CrossrefPubMedGoogle Scholar
  • 24 Dietrich J, Wang D, Batchelor T T. Cediranib: profile of a novel anti-angiogenic agent in patients with glioblastoma.  Expert Opin Investig Drugs. 2009;  18 1549-1557
    CrossrefPubMedGoogle Scholar
  • 25 Karakunnel J J, Gulley J L, Arlen P M et al. Phase II trial of AZD2171 in docetaxel-resistant, castrate-resistant prostate cancer (CRPC).  J Clin Oncol. 2008;  26 (May 20 Suppl.) Abstr. 5136
    PubMedGoogle Scholar
  • 26 Sridhar S S, Mackenzie M J, Hotte S J et al. Activity of cediranib (AZD2171) in patients (pts) with previously untreated metastatic renal cell cancer (RCC): a phase II trial of the PMH Consortium.  J Clin Oncol. 2008;  26 Abstr. 5047
    PubMedGoogle Scholar
  • 27 Ramalingam S S, Mack P C, Vokes E E et al. Cediranib (AZD2171) for the treatment of recurrent small cell lung cancer (SCLC): a California Consortium phase II study (NCI # 7097).  J Clin Oncol. 2008;  26 Abstr. 8078
    PubMedGoogle Scholar
  • 28 Matulonis U A, Berlin S, Ivy P et al. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer.  J Clin Oncol. 2009;  27 5601-5606
    CrossrefPubMedGoogle Scholar
  • 29 Mross K, Stefanic M, Gmehling D et al. Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors.  J Clin Cancer Res. 2010;  16 311-319
    PubMedGoogle Scholar
  • 30 Ledermann J, Rustin G, Hackshaw A et al. A randomized phase II placebo-controlled trial using maintenance therapy to evaluate the vascular targeting agent BIBF 1120 following treatment of relapsed ovarian cancer (OC).  J Clin Oncol. 2009;  27 (Suppl.) Abstr. 5501
    PubMedGoogle Scholar
  • 31 du Bois A, Huober J, Stopfer P et al. A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies.  Ann Oncol. 2009;  21 370-375
    CrossrefPubMedGoogle Scholar
  • 32 Hutson T E, Davis I D, Machiels J P et al. Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma.  J Clin Oncol. 2010;  28 475-480
    CrossrefPubMedGoogle Scholar
  • 33 Sleijfer S, Ray-Coquard I, Papai Z et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043).  J Clin Oncol. 2009;  27 3126-3132
    CrossrefPubMedGoogle Scholar
  • 34 Nikolinakos P G, Altorki N, Yankelevitz D et al. Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib.  Cancer Res. 2010;  70 2171-2179
    CrossrefPubMedGoogle Scholar
  • 35 Friedlander M, Hancock K, Benigno B et al. Pazopanib (GW786034) is active in women with advanced epithelial ovarian, fallopian tube, and peritoneal cancers: final results of a phase II study. Stockholm: ESMO Congress; 2008: Abstr. 5561
    Google Scholar
  • 36 Gao D, Nolan D J, Mellick A S et al. Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis.  Science. 2008;  319 195-198
    CrossrefPubMedGoogle Scholar
  • 37 Biagi J, Oza A, Grimshaw R et al. A phase II study of sunitinib (SU11248) in patients (pts) with recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma – NCIC CTG IND 185.  J Clin Oncol. 2008;  26 (May 20 Suppl.) Abstr. 5522
    PubMedGoogle Scholar
  • 38 Wilhelm S M, Carter C, Tang L et al. BAY 43–9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.  Cancer Res. 2004;  64 7099-7109
    CrossrefPubMedGoogle Scholar
  • 39 Kolch W. Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions.  Biochem J. 2000;  351 289-305
    CrossrefPubMedGoogle Scholar
  • 40 Pietras K, Rubin K, Sjoblom T et al. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy.  Cancer Res. 2002;  62 5476-5484
    PubMedGoogle Scholar
  • 41 Baranowska-Kortylewicz J, Abe M, Pietras K et al. Effect of platelet-derived growth factor receptor-beta inhibition with STI571 on radioimmunotherapy.  Cancer Res. 2005;  65 7824-7831
    PubMedGoogle Scholar
  • 42 Henriksen R, Funa K, Wilander E et al. Expression and prognostic significance of platelet-derived growth factor and its receptors in epithelial ovarian neoplasms.  Cancer Res. 1993;  53 4550-4554
    PubMedGoogle Scholar
  • 43 Buchdunger E, Zimmermann J, Mett H et al. Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class.  Proc Natl Acad Sci USA. 1995;  92 2558-2562
    CrossrefPubMedGoogle Scholar
  • 44 Alberts D S, Liu P Y, Wilczynski S P et al. Phase II trial of imatinib mesylate in recurrent, biomarker positive, ovarian cancer (Southwest Oncology Group Protocol S0211).  Int J Gynecol Cancer. 2007;  17 784-788
    CrossrefPubMedGoogle Scholar
  • 45 Coleman R L, Broaddus R R, Bodurka D C et al. Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers.  Gynecol Oncol. 2006;  101 126-131
    CrossrefPubMedGoogle Scholar
  • 46 Posadas E M, Kwitkowski V, Kotz H L et al. A prospective analysis of imatinib-induced c-KIT modulation in ovarian cancer: a phase II clinical study with proteomic profiling.  Cancer. 2007;  110 309-317
    CrossrefPubMedGoogle Scholar
  • 47 Matei D, Emerson R E, Schilder J et al. Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis: a Hoosier Oncology Group trial.  Cancer. 2008;  113 723-732
    CrossrefPubMedGoogle Scholar
  • 48 Rote Liste® Service GmbH .Fachinformationen. Im Internet:. http://www.fachinfo.de Stand: 28.7.2010
    Google Scholar
  • 49 Beijnen J H, Schellens J H. Drug interactions in oncology.  Lancet Oncol. 2004;  5 489-496
    CrossrefPubMedGoogle Scholar
  • 50 Nimeiri H S, Oza A M, Morgan R J et al. Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia.  Gynecol Oncol. 2008;  110 49-55
    CrossrefPubMedGoogle Scholar
  • 51 Annunziata C M, Walker A J, Minasian L et al. Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2.  Clin Cancer Res. 2010;  16 664-672
    CrossrefPubMedGoogle Scholar
  • 52 Lobov I B, Renard R A, Papadopoulos N et al. Delta-like ligand 4 (Dll4) is induced by VEGF as a negative regulator of angiogenic sprouting.  Proc Natl Acad Sci USA. 2007;  104 3219-3224
    CrossrefPubMedGoogle Scholar

Dr. Florian Heitz

Abteilung für Gynäkologie und gynäkologische Onkologie
Dr. Horst Schmidt Kliniken

Ludwig-Erhard-Straße 100

65199 Wiesbaden

Email: florian.heitz@gmx.net

      >